F. No. 12(7)/2021/DP/NPPA/Div.II/ Vol-IV National Pharmaceutical Pricing Authority

Subject: Minutes of the 49th meeting of the Multidisciplinary Committee of Experts held on 23.02.2023 at 11:00 AM.

49th meeting of the "Multidisciplinary Committee of Experts" was held on 23.02.2023 at 11:00AMunder the convenorship of Shri Manmohan Sachdeva, Advisor (Cost), through video-conferencing. The following members attended the meeting through video conferencing: -

- 1. Shri A.K. Pradhan, Jt. Drugs Controller, CDSCO
- 2. Dr. J. J. Cherian, Scientist-D, ICMR
- 3. Dr. Rakesh Kr. Singh, Associate Professor, NIPER Raebareli
- 4. Prof. Y. K. Gupta, Principal Scientific Advisor (projects), THSTI-DBT, GoI & Ex-HoD, Pharmacology & Dean (Academics), AIIMS, New Delhi – Co-opted member
- 5. Dr. Pooja Gupta, Associate Professor, Department of Pharmacology, AIIMS-New Delhi.

The following officers of NPPA attended and presented the cases before the Committee

- 1. Ms. Rashmi Tahiliani, Jt. Director (Pricing)
- 2. Shri Mahaveer Saini, Deputy Director (Pricing), NPPA
- Sh. Gaurav Gupta represented Dr. Jai Prakash, Sr. Principal Scientific Officer, Indian Pharmacopea Commission – Co-opted member through video conferencing

1. Agenda No. 1 - Retail price fixation under Para 5 of DPCO, 2013 - Fixed Dose Combinations (FDCs) of Dapagliflozin + Sitagliptin + Metformin tablet.

- 1.1.The Committee noted that 2 applications have been received for retail price fixation of two Fixed Dose Combinations (FDCs) of Dapagliflozin + Sitagliptin + Metformin tablets i.e. (i) Dapagliflozin 10 mg + Sitagliptin 100 mg + Metformin (ER) 1000 mg Tablet, (ii) Dapagliflozin 10 mg + Sitagliptin 100 mg + Metformin (ER) 500 mg tablet. The Committee further noted that the formulation 'Dapagliflozin and Sitagliptin' of the FDCs were patented and the patent expired in October, 2020 and $5^{th}/6^{th}$ July, 2022 respectively.
- 1.2. In this connection, it is mentioned that the Authority in its $96^{\,\mathrm{th}}$ meeting dated 24.03.2022 (based on the recommendation of the Committee of Experts in its $40^{\,\mathrm{th}}$ meeting dated 14.03.2022) approved the retail price of the FDC of Sitagliptin + Metformin tablet in line with the following methodology as detailed below:
 - (i) The Authority noted that the formulation "Sitagliptin" has become/is on the verge of becoming off-patent and observed that, in line with the decision taken in its 89th meeting dated 28.06.2021, if the calculation is based on six month prior market data, the price of the patented period would be taken into



consideration and hence the price rationalisation due to expiry of the patent may not pass on to the patients.

(ii) The Authority further noted that matter was placed before the 40th meeting of the Multidisciplinary Committee of Experts held on 14.03.2022 which in line decision taken in the 89th Authority meeting dated 28.06.2021, recommended to fix the retail price as per the following methodology:

"....The Committee observed that the market data of the FDCs of Sitagliptin and Metformin tablet is also available and noted that if the retail price is calculated based on six month prior market data, the price of patented period would be taken into consideration and benefit of price reduction due to medicines which has become/ is on the verge of becoming off-patent would not pass not on to the consumers. The Committee deliberated upon the matter in detail and is of the opinion that the price of drugs be reduced in respect of the drugs which has become/ on the verge of becoming off-patent so as to pass the benefit of price reduction to the consumers and that a reduction of 50% be allowed on the patented component of FDCs i.e. 'Sitagliptin' to arrive at the retail price. Accordingly, the Committee recommended to allow retail price for the FDCs of Sitagliptin and Metformin tablet in line with the decision taken in its 33rd meeting held on 21.06.2021. However, where the calculated retail price of the FDC of formulation based on six month prior market data as per the provisions of DPCO 2013 is lower than claimed price and the calculated price, the Committee recommended that the same would be allowed."

(iii) The Authority deliberated upon the matter in detail and accepted the recommendation of the Multidisciplinary Committee of Experts and approved the fixation of the new drugs as per the methodology stated by the Multidisciplinary Committee of Experts.

- 1.3. The Authority further approved the retail prices of FDCs as stated in above para 1.2 in its 97^{th} , 99^{th} , 100^{th} , 101^{st} , 102^{nd} , 103^{rd} , 106^{th} and 109^{th} meeting dated 06.05.2022, 28.06.2022, 05.08.2022, 07.09.2022, 27.09.2022, 10.11.2022, 30.12.2022 and 21.02.2023 based on the recommendation made by the Multidisciplinary Committee of Experts in its 41^{st} , 42^{nd} , 43^{rd} , 44^{th} , 45^{th} , 46^{th} , 47^{th} and 48^{th} meeting dated 08.04.2022, 02.06.2022, 04.07.2022, 04.08.2022, 13.09.2022, 19.10.2022, 02.12.2022and 20.01.2023 as per the above mentioned methodology.
- 1.4. Accordingly, the retail price of these FDCs has been attempted in line with principles as adopted earlier i.e., reduction of 50% from the patented component i.e., Dapagliflozin [termed as (a)] and Sitagliptin [termed as (b)] and then adding the ceiling price of the scheduled components as applicable six month earlier from the date of application [termed as (e)]. From the total, a reduction of 20% of the lower of (b), (d) and (e) is provided drawing reference from para No. 3.2 of Pronab Sen Committee Report and also as per the precedent followed in the similar cases.
- 1.5. Accordingly, the draft price calculation as per methodology as mentioned in Para 5 was placed as Agenda Item No. 1 (i) to 1 (ii) for kind deliberations of the Committee. Further, the calculation as per Para 5 of DPCO 2013, based on the market data available in Pharmatrac, if any, is also calculated.
- 1.6 Accordingly, the Committee deliberated on the agenda item in detail and recommended the retail price of FDCs of Dapagliflozin + Sitagliptin + Metformin Hydrochloride IP tablet for various companies as detailed below:

1.6.1 Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg + Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100mg + Metformin Hydrochloride IP 500mg (as Extended Release) for M/s Exemed Pharmaceuticals (manufacturer) and M/s Wockhardt Limited (marketer)at Rs. 16.95 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Patent Component		
(a)	Calculated retail price of Dapagliflozin 10 mg tablet	(as per June, 2022 data)	14.96
(b)	50% of Patent Component		7.48
(c)	Calculated retail price of Sitagliptin 100 mg tablet	(as per June, 2022 data)	35.50
(d)	50% of Patent Component	(a) 1 (a) 1	17.75
(e)	Metformin CR 500 mg	Ceiling Price [SO. 1499(E) dated 30.03.2022]	2.13
(f)	Less 20% of the lower of (b), (d) and (e)		0.43
(g)	Worked out Retail Price (b)+(d)+(e)-(f)	W. SEE - 1	26.93
(h)	Claimed Retail price		16.95
(i)	Retail price as per Pharmatrac Data for June, 2022		NA
(j)	Recommended retail price		16.95

1.6.2.Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg + Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100mg + Metformin Hydrochloride IP 1000mg (as extended release) for M/s Exemed pharmaceuticals (manufacturer) and M/s Wockhardt Limited (marketer)at Rs. 17.84 per tablet excluding GST as detailed below:

Particulars	Source/Method	Amount (Rs.)
Patent Component	ATTENDED TO LOT	
Calculated retail price of Dapagliflozin 10 mg tablet	Retail price (as per June, 2022 data)	14.96
50% of Patent Component		7.48
Calculated retail price of Sitagliptin 100	Retail price (as per	35.50
	Patent Component Calculated retail price of Dapagliflozin 10 mg tablet 50% of Patent Component	Patent Component Calculated retail price of Dapagliflozin 10 mg tablet Solve of Patent Component Retail price (as per June, 2022 data)

S. No.	Particulars	Source/Method	Amount (Rs.)
	mg tablet	June, 2022 data)	
(d)	50% of Patent Component		17.75
(e)	Metformin CR 1000 mg	Ceiling Price [SO. 1499(E) dated 30.03.2022]	4.05
(f)	Less 20% of the lower of (b), (d) and (e)		0.81
(g)	Worked out Retail Price (b)+(d)+(e)-(f)	-	28.47
(h)	Claimed Retail price		17.84
(i)	Retail price as per Pharmatrac Data for June, 2022		NA
(j)	Recommended retail price		17.84

- 2. Agenda No. 2 Retail price fixation under Para 5 of DPCO, 2013 Fixed Dose Combinations (FDCs) of Dapagliflozin + Vildagliptin (as sustained release) + Metformin(as sustained release) tablet.
- 2.1. The committee noted that total of 2 applications have been received for the FDC of Dapagliflozin + Vildagliptin (as sustained release) + Metformin(as sustained release) tablet. The committee further noted that the component Dapagliflozin and Vildagliptin of the FDCs were patented and the patent expired on 02.10.2020 and 09.12.2019 respectively.
- 2.2. In this connection, it may be mentioned that the Authority in its 103rd meeting dated 10.11.2022 (based on the recommendation of the Committee of Experts in its 46th meeting dated 19.10.2022) approved the retail price of the FDC of Dapagliflozin + Sitagliptin + Metformin in line with the methodology decided in its 96th meeting dated 24.03.2022 (based on the recommendation of the Committee of Experts in its 40th meeting dated 14.03.2022) for the calculation of retail price of the FDC of Sitagliptin + Metformin tablet in line with the methodology as detailed below:
 - (i) The Authority noted that the formulation "Sitagliptin" has become/ is on the verge of becoming off-patent and observed that, in line with the decision taken in its 89th meeting dated 28.06.2021, if the calculation is based on six month prior market data, the price of the patented period would be taken into consideration and hence the price rationalisation due to expiry of the patent may not pass on to the patients.
 - (ii) The Authority further noted that matter was placed before the 40th meeting of the Multidisciplinary Committee of Experts held on 14.03.2022 which in line decision taken in the 89th Authority meeting dated 28.06.2021, recommended to fix the retail price as per the following methodology:
 - "....The Committee observed that the market data of the FDCs of Sitagliptin and Metformin tablet is also available and noted that if the retail price is calculated based on six month prior market data, the price of patented period would be taken into consideration and benefit of price reduction due to

medicines which has become/ is on the verge of becoming off-patent would not pass not on to the consumers. The Committee deliberated upon the matter in detail and is of the opinion that the price of drugs be reduced in respect of the drugs which has become/ on the verge of becoming off-patent so as to pass the benefit of price reduction to the consumers and that a reduction of 50% be allowed on the patented component of FDCs i.e. 'Sitagliptin' to arrive at the retail price. Accordingly, the Committee recommended to allow retail price for the FDCs of Sitagliptin and Metformin tablet in line with the decision taken in its 33rd meeting held on 21.06.2021. However, where the calculated retail price of the FDC of formulation based on six month prior market data as per the provisions of DPCO 2013 is lower than claimed price and the calculated price, the Committee recommended that the same would be allowed."

- (iii) The Authority deliberated upon the matter in detail and accepted the recommendation of the Multidisciplinary Committee of Experts and approved the fixation of the new drugs as per the methodology stated by the Multidisciplinary Committee of Experts.
- 2.3. The Authority further approved the retail prices of FDCs as stated in above para 2.2 in its 97th, 99th,100th, 101st, 102nd, 103rd, 106th and 109thmeeting dated 06.05.2022, 28.06.2022, 05.08.2022, 07.09.2022, 27.09.2022, 10.11.2022, 30.12.2022 and 21.02.2023 based on the recommendation made by the Multidisciplinary Committee of Experts in its 41st, 42nd, 43rd, 44th, 45th, 46th, 47th and 48thmeeting dated 08.04.2022, 02.06.2022, 04.07.2022, 04.08.2022, 13.09.2022, 19.10.2022, 02.12.2022 and 20.01.2023 as per the above mentioned methodology.
- 2.4. Accordingly, the retail price of these FDCs was calculated in line with principles as adopted earlier i.e., reduction of 50% from the patented component i.e., Dapagliflozin [termed as (a)] and Vildagliptin [termed as (b)] and then adding the ceiling price of the scheduled components as applicable six month earlier from the date of application [termed as (e)]. From the total, a reduction of 20% of the lower of (b), (d) and (e) is provided drawing reference from para No. 3.2 of Pronab Sen Committee Report and also as per the precedent followed in the similar cases.
- 2.5. Accordingly, the Committee deliberated upon the same and recommended the retail price of FDCs of Dapagliflozin + Vildagliptin (as sustained release) + Metformin (as sustained release) tablet for various companies as detailed below:
- 2.6.1 Each uncoated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg + Vildagliptin 100mg (as sustained release) + Metformin Hydrochloride IP 500mg (as sustained release) for M/s Alkem Laboratories Ltd. (marketer) and M/s Ravenbhel Healthcare Pvt. Ltd. (manufacturer)at Rs. 14.84 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Patent Component		
(a)	Calculated retail price of Dapagliflozin 10 mg tablet	Retail price (as per June, 2022 data)	14.96
(b)	50% of Patent Component	NYSUL THE R	7.48
(c)	Calculated retail price of Vildagliptin 100 mg (as sustained Release) tablet	Retail price (as per June, 2022 data)	11.32

S. No.	Particulars	Source/Method	Amount (Rs.)
(d)	50% of Patent Component		5.66
(e)	Metformin CR 500 mg	Ceiling Price [SO. 1499(E) dated 30.03.2022]	2.13
(f)	Less 20% of the lower of (b), (d) and (e)		0.43
(g)	Worked out Retail Price (b)+(d)+(e)-(f)		14.84
(h)	Claimed Retail price		27.67
(i)	Retail price as per Pharmatrac Data for June, 2022		NA
(j)	Recommended retail price		14.84

2.6.2- Each uncoated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg + Vildagliptin 100mg (as sustained release) + Metformin Hydrochloride IP 1000mg (as sustained release) for M/s Alkem Laboratories Ltd. (marketer) and M/s Ravenbhel Healthcare Pvt. Ltd. (manufacturer)at Rs. 16.38 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Patent Component		
(a)	Calculated retail price of Dapagliflozin 10 mg tablet	Retail price (as per June, 2022 data)	14.96
(b)	50% of Patent Component		7.48
(c)	Calculated retail price of Vildagliptin 100 mg (as sustained Release) tablet	Retail price (as per June, 2022 data)	11.32
(d)	50% of Patent Component		5.66
(e)	Metformin CR 1000 mg	Ceiling Price [SO. 1499(E) dated 30.03.2022]	4.05
(f)	Less 20% of the lower of (b), (d) and (e)		0.81
(g)	Worked out Retail Price (b)+(d)+(e)-(f)		16.38
(h)	Claimed Retail price		29.46
(i)	Retail price as per Pharmatrac Data for June, 2022		NA
(j)	Recommended retail price		16.38

- 3. Agenda No. 3 Retail price fixation under Para 5 of DPCO, 2013 Fixed Dose Combinations (FDCs) of Vildagliptin (as sustained release) + Metformin (as sustained release) tablet.
- 3.1. The committee noted that total of 12 applications have been received for the FDC of Vildagliptin (as sustained release) + Metformin(as sustained release) tablet. The committee further noted that the component Vildagliptin of the FDCs was patented and the patent expired on 09.12.2019 respectively.
- 3.2. Further, NPPA has earlier fixed the retail prices of FDCs of Vildagliptin (IR)+ Metformin (IR/SR) based on the basis of decision taken in 72nd meeting of Authority

held on 20.01.2020 regarding retail price fixation of Fixed Dose Combinations (FDCs) of Metformin and Vildagliptin tablets in which it emphasized that the benefit of price reduction in case of formulations becoming off-patent ought to be passed on to the consumers in public interest. It was decided to fix the retail price of FDCs of Metformin and Vildagliptin tablet by adding 16% retailer margin to the average Price to Retailer (PTR) based on Form V- data submitted by the companies for whom retail prices were earlier approved for FDCs of Metformin and Vildagliptin tablets to give the benefits of patent expiry of the drug Vildagliptin to consumers.

- 3.3. In this connection, it is stated that NPPA has earlier not fixed the retail price of FDCs of Vildagliptin (SR)+ Metformin (IR/SR), and the data for the same is also not available in the Pharmatrac database. Therefore, the retail price of FDCs of Vildagliptin (SR)+ Metformin (SR) are proposed to be fixed in line with the methodology decided in its $96^{\,\mathrm{th}}$ meeting dated 24.03.2022 (based on the recommendation of the Committee of Experts in its $40^{\,\mathrm{th}}$ meeting dated 14.03.2022) for the calculation of retail price of the FDC of Sitagliptin + Metformin tablet in line with the methodology as detailed below:
 - (i) The Authority noted that the formulation "Sitagliptin" has become/is on the verge of becoming off-patent and observed that, in line with the decision taken in its 89th meeting dated 28.06.2021, if the calculation is based on six month prior market data, the price of the patented period would be taken into consideration and hence the price rationalisation due to expiry of the patent may not pass on to the patients.
 - (ii) The Authority further noted that matter was placed before the 40th meeting of the Multidisciplinary Committee of Experts held on 14.03.2022 which in line decision taken in the 89th Authority meeting dated 28.06.2021, recommended to fix the retail price as per the following methodology:
 - "....The Committee observed that the market data of the FDCs of Sitagliptin and Metformin tablet is also available and noted that if the retail price is calculated based on six month prior market data, the price of patented period would be taken into consideration and benefit of price reduction due to medicines which has become/ is on the verge of becoming off-patent would not pass not on to the consumers. The Committee deliberated upon the matter in detail and is of the opinion that the price of drugs be reduced in respect of the drugs which has become/ on the verge of becoming off-patent so as to pass the benefit of price reduction to the consumers and that a reduction of 50% be allowed on the patented component of FDCs i.e. 'Sitagliptin' to arrive at the retail price. Accordingly, the Committee recommended to allow retail price for the FDCs of Sitagliptin and Metformin tablet in line with the decision taken in its 33rd meeting held on 21.06.2021. However, where the calculated retail price of the FDC of formulation based on six month prior market data as per the provisions of DPCO 2013 is lower than claimed price and the calculated price, the Committee recommended that the same would be allowed."
 - (iii) The Authority deliberated upon the matter in detail and accepted the recommendation of the Multidisciplinary Committee of Experts and approved

the fixation of the new drugs as per the methodology stated by the Multidisciplinary Committee of Experts.

- 3.4. The Authority further approved the retail prices of FDCs as stated in above para 2.2 in its 97th, 99th,100th, 101st, 102nd, $103^{\rm rd}$, 106th and $109^{\rm th}$ meeting dated 06.05.2022, 28.06.2022, 05.08.2022, 07.09.2022, 27.09.2022, 10.11.2022, 30.12.2022 and 21.02.2023 based on the recommendation made by the Multidisciplinary Committee of Experts in its 41st, 42nd, 43rd, 44th, 45th, 46th, 47th and 48th meeting dated 08.04.2022, 02.06.2022, 04.07.2022, 04.08.2022, 13.09.2022, 19.10.2022, 02.12.2022 and 20.01.2023 as per the above mentioned methodology.
- 3.5. Accordingly, the retail price of these FDCs was calculated in line with principles as adopted earlier i.e., reduction of 50% from the patented component i.e., Vildagliptin SR [termed as (b)] and then adding the ceiling price of the scheduled components as applicable six month earlier from the date of application [termed as (c)]. From the total, a reduction of 20% of the lower of (b) and (c) is provided drawing reference from para No. 3.2 of Pronab Sen Committee Report and also as per the precedent followed in the similar cases.
- 3.6. Accordingly, the Committee deliberated upon the same and recommended the retail price of FDCs of Dapagliflozin + Vildagliptin (as sustained release) + Metformin (as sustained release) tabletfor various companies as detailed below:
- 3.6.1- Each film coated bilayered tablet contains: Vildagliptin (as sustained release) 100mg + Metformin Hydrochloride IP (as sustained release) 500mg for M/s Synokem Pharmaceuticals Ltd. (manufacturer) and M/s Intas Pharmaceuticals Ltd (marketer)at Rs. 7.36per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Patent Component		
(a)	Calculated retail price of Vildagliptin 100 mg (as sustained Release) tablet	Retail price (as per June, 2022 data)	11.32
(b)	50% of Patent Component		5.66
(c)	Metformin CR 500 mg	Ceiling Price [SO. 1499(E) dated 30.03.2022]	2.13
(d)	Less 20% of the lower of (b) and (c)		0.43
(e)	Worked out Retail Price (b)+(c)-(d)		7.36
(f)	Claimed Retail price		12.50
(g)	Retail price as per Pharmatrac Data for June, 2022		NA
(h)	Recommended retail price		7.36

3.6.2- Each film coated bilayered tablet contains: Vildagliptin (as sustained release) 100mg + Metformin Hydrochloride IP (as sustained release) 500mg for M/s Synokem Pharmaceuticals Ltd. (manufacturer) and M/s Torrent Pharmaceuticals Ltd (marketer) at Rs. 7.36per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Patent Component		
(a)	Calculated retail price of Vildagliptin 100 mg (as sustained Release) tablet	Retail price (as per June, 2022 data)	11.32
(b)	50% of Patent Component		5.66
(c)	Metformin CR 500 mg	Ceiling Price [SO. 1499(E) dated 30.03.2022]	2.13
(d)	Less 20% of the lower of (b) and (c)		0.43
(e)	Worked out Retail Price (b)+(c)-(d)		7.36
(f)	Claimed Retail price		13.50
(g)	Retail price as per Pharmatrac Data for June, 2022		NA
(h)	Recommended retail price		7.36

3.6.3– Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release) + Metformin Hydrochloride IP 500mg (as Sustained Release) for M/s Synokem Pharmaceuticals Pvt. Ltd. (manufacturer) and M/s Zydus Healthcare Limited (marketer) at Rs. 7.43per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Patent Component		
(a)	Calculated retail price of Vildagliptin 100 mg (as sustained Release) tablet	Retail price (as per July, 2022 data)	11.46
(b)	50% of Patent Component		5.73
(c)	Metformin CR 500 mg	Ceiling Price [SO. 1499(E) dated 30.03.2022]	2.13
(d)	Less 20% of the lower of (b) and (c)		0.43
(e)	Worked out Retail Price (b)+(c)-(d)		7.43
(f)	Claimed Retail price		20.00
(g)	Retail price as per Pharmatrac Data for July, 2022		NA
(h)	Recommended retail price		7.43

3.6.4- Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release) + Metformin Hydrochloride IP 500mg (As Sustained Release) for M/s Synokem pharmaceuticals Pvt. Ltd. (manufacturer) and M/s Lupin Limited (marketer)at Rs. 7.43per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Patent Component		
(a)	Calculated retail price of Vildagliptin 100 mg (as sustained Release) tablet	Retail price (as per July, 2022 data)	11.46
(b)	50% of Patent Component		5.73
(c)	Metformin CR 500 mg	Ceiling Price [SO. 1499(E) dated 30.03.2022]	2.13



S. No.	Particulars	Source/Method	Amount (Rs.)
(d)	Less 20% of the lower of (b) and (c)		0.43
(e)	Worked out Retail Price (b)+(c)-(d)		7.43
(f)	Claimed Retail price		13.39
(g)	Retail price as per Pharmatrac Data for July, 2022	Market 1	NA
(h)	Recommended retail price		7.43

3.6.5- Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release) + Metformin Hydrochloride IP 500mg (As Sustained Release) for M/s Synokem pharmaceuticals Pvt. Ltd. (manufacturer) and M/s Eris Lifesciences Limited (marketer) at Rs. 7.43per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Patent Component		To the state of the
(a)	Calculated retail price of Vildagliptin 100 mg (as sustained Release) tablet	Retail price (as per July, 2022 data)	11.46
(b)	50% of Patent Component		5.73
(c)	Metformin CR 500 mg	Ceiling Price [SO. 1499(E) dated 30.03.2022]	2.13
(d)	Less 20% of the lower of (b) and (c)	Market Market	0.43
(e)	Worked out Retail Price (b)+(c)-(d)		7.43
(f)	Claimed Retail price		22.32
(g)	Retail price as per Pharmatrac Data for July, 2022		NA
(h)	Recommended retail price		7.43

3.6.6– Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release) + Metformin Hydrochloride IP 500mg (As Sustained Release) for M/s Synokem pharmaceuticals Pvt. Ltd. (manufacturer) and M/s Cipla Limited (marketer)at Rs. 7.43per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Patent Component		
(a)	Calculated retail price of Vildagliptin 100 mg (as sustained Release) tablet	Retail price (as per July, 2022 data)	11.46
(b)	50% of Patent Component		5.73
(c)	Metformin CR 500 mg	Ceiling Price [SO. 1499(E) dated 30.03.2022]	2.13
(d)	Less 20% of the lower of (b) and (c)		0.43
(e)	Worked out Retail Price (b)+(c)-(d)		7.43
(f)	Claimed Retail price		25.00
(g)	Retail price as per Pharmatrac Data for July, 2022		NA

S. No.	Particulars	Source/Method	Amount (Rs.)
(h)	Recommended retail price		7.43

3.6.7– Each film coated bilayered tablet contains: Vildagliptin (as sustained release) $100 \, \text{mg} + \text{Metformin Hydrochloride IP}$ (as sustained release) $1000 \, \text{mg}$ for M/s Synokem Pharmaceuticals Ltd. (manufacturer) and M/s Intas Pharmaceuticals Ltd (marketer) at Rs. $8.90 \, \text{per}$ tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Patent Component	TO STATE OF THE ST	Hall to the last
(a)	Calculated retail price of Vildagliptin 100 mg (as sustained Release) tablet	Retail price (as per June, 2022 data)	11.32
(b)	50% of Patent Component		5.66
(c)	Metformin CR 1000 mg	Ceiling Price [SO. 1499(E) dated 30.03.2022]	4.05
(d)	Less 20% of the lower of (b) and (c)		0.81
(e)	Worked out Retail Price (b)+(c)-(d)		8.90
(f)	Claimed Retail price	THE STATE OF THE S	15.00
(g)	Retail price as per Pharmatrac Data for June, 2022		NA
(h)	Recommended retail price		8.90

3.6.8- Each film coated bilayered tablet contains: Vildagliptin (as sustained release) 100mg + Metformin Hydrochloride IP (as sustained release) 1000mg for M/s Synokem Pharmaceuticals Ltd. (manufacturer) and M/s Torrent Pharmaceuticals Ltd (marketer) at Rs. 8.90 per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Patent Component		
(a)	Calculated retail price of Vildagliptin 100 mg (as sustained Release) tablet	Retail price (as per June, 2022 data)	11.32
(b)	50% of Patent Component	in a little win a single	5.66
(c)	Metformin CR 1000 mg	Ceiling Price [SO. 1499(E) dated 30.03.2022]	4.05
(d)	Less 20% of the lower of (b) and (c)		0.81
(e)	Worked out Retail Price (b)+(c)-(d)		8.90
(f)	Claimed Retail price		14.50
(g)	Retail price as per Pharmatrac Data for June, 2022		NA
(h)	Recommended retail price		8.90

3.6.9– Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release) + Metformin Hydrochloride IP 1000mg (as Sustained Release) for M/s Synokem Pharmaceuticals Pvt. Ltd. (manufacturer) and M/s Lupin Limited (marketer) at Rs. 8.97per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)

	Patent Component		
(a)	Calculated retail price of Vildagliptin 100 mg (as sustained Release) tablet	Retail price (as per July, 2022 data)	11.46
(b)	50% of Patent Component		5.73
(c)	Metformin CR 1000 mg	Ceiling Price [SO. 1499(E) dated 30.03.2022]	4.05
(d)	Less 20% of the lower of (b) and (c)		0.81
(e)	Worked out Retail Price (b)+(c)-(d)		8.97
(f)	Claimed Retail price		15.17
(g)	Retail price" as per Pharmatrac Data for July, 2022		NA
(h)	Recommended retail price	DUNE STREET	8.97

3.6.10- Each film coated bilayered tablet contains: Vildagliptin (as sustained release) 100mg + Metformin Hydrochloride IP (as sustained release) 1000mg for M/s Synokem Pharmaceuticals Ltd. (manufacturer) and M/s Zydus Healthcare Limited (marketer)at Rs. 8.97per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Patent Component		
(a)	Calculated retail price of Vildagliptin 100 mg (as sustained Release) tablet	Retail price (as per July, 2022 data)	11.46
(b)	50% of Patent Component		5.73
(c)	Metformin CR 1000 mg	Ceiling Price [SO. 1499(E) dated 30.03.2022]	4.05
(d)	Less 20% of the lower of (b) and (c)		0.81
(e)	Worked out Retail Price (b)+(c)-(d)		8.97
(f)	Claimed Retail price		25.00
(g)	Retail price as per Pharmatrac Data for July, 2022		NA
(h)	Recommended retail price	THE WALL THE	8.97

3.6.11- Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release) + Metformin Hydrochloride IP 1000mg (as Sustained Release) for M/s Synokem Pharmaceuticals Pvt. Ltd. (manufacturer) and M/s Eris Lifesciences Limited (marketer)at Rs. 8.97per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Patent Component		IN TOUR
(a)	Calculated retail price of Vildagliptin 100 mg (as sustained Release) tablet	Retail price (as per July, 2022 data)	11.46
(b)	50% of Patent Component		5.73
(c)	Metformin CR 1000 mg	Ceiling Price [SO. 1499(E) dated 30.03.2022]	4.05



(d)	Less 20% of the lower of (b) and (c)	0.81
(e)	Worked out Retail Price (b)+(c)-(d)	8.97
(f)	Claimed Retail price	26.78
(g)	Retail price as per Pharmatrac Data for July, 2022	NA
(h)	Recommended retail price	8.97

3.6.12- Each film coated bilayered tablet contains: Vildagliptin IP 100mg (As Sustained Release) + Metformin Hydrochloride IP 1000mg (as Sustained Release) for M/s Synokem Pharmaceuticals Pvt. Ltd. (manufacturer) and M/s Cipla Limited (marketer)at Rs. 8.97per tablet excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Patent Component		
(a)	Calculated retail price of Vildagliptin 100 mg (as sustained Release) tablet	Retail price (as per July, 2022 data)	11.46
(b)	50% of Patent Component		5.73
(c)	Metformin CR 1000 mg	Ceiling Price [SO. 1499(E) dated 30.03.2022]	4.05
(d)	Less 20% of the lower of (b) and (c)		0.81
(e)	Worked out Retail Price (b)+(c)-(d)		8.97
(f)	Claimed Retail price		30.00
(g)	Retail price as per Pharmatrac Data for July, 2022		NA
(h)	Recommended retail price		8.97

4. Agenda No. 4- Each Sachet of 4.38g contains: Zinc Sulphate Monohydrate IP 0.011g + Sodium Citrate IP 0.58g + Potassium Chloride IP 0.30g + Sodium Chloride IP 0.52g + Dextrose Anhydrous IP 2.70g for M/s FDC Ltd. (manufacturer) and M/s FDC Ltd. (marketer)

4.1 The committee deliberated on the matter and recommended the retail price for Each Sachet of 4.38g containing Zinc Sulphate Monohydrate IP 0.011g + Sodium Citrate IP 0.58g + Potassium Chloride IP 0.30g + Sodium Chloride IP 0.52g + Dextrose Anhydrous IP 2.70g for M/s FDC Ltd. (manufacturer) and M/s FDC Ltd. (marketer) of Rs. 6.12 per ml excluding GST as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Each Sachet of 4.38g contains: Zinc Sulphate Monohydrate IP 0.011g + Sodium Citrate IP 0.58g + Potassium Chloride IP 0.30g + Sodium Chloride IP 0.52g + Dextrose Anhydrous IP 2.70g		
(a)	Calculated retail price of Zinc Sulphate Monohydrate IP 0.011g	Note 1	2.23
(b)	Sodium Citrate IP 0.58g + Potassium Chloride IP 0.30g + Sodium Chloride IP 0.52g + Dextrose Anhydrous IP	ORS Sachet (as	4.33

	2.70g (ORS Sachet)	No. 1499(E) dated 30.03.2022 (0.99 per GM *)	
(d)	Less 20% of the lower of (b) and (c)		0.44
	Worked out Retail Price (b)+(c)-(d)		6.12
(e) (f)	Claimed Retail price		10.00
(g)	Recommended retail price		6.12

Note 1: Calculation of Retail Price of Zinc Sulphate Monohydrate IP 0.011g powder

(i) Present applicable ceiling price of Zinc Sulphate Dispersible Tablet 20 mg =

Rs 3.49 per tablet.

(ii) Therefore, the derived Retail Price for Zinc Sulphate Monohydrate IP 0.011 g or 11 mg =

Derived retail price as per recommendation of Pronab Sen committee:

 $P(s) = P^*[1+a.\{(s-s^*)/s^*\}]$

Where: P(s) = Price ceiling of the strength

P* = price ceiling for reference strength

s = strength in terms of API content

s* = reference strength

a= 0.8 for tablet / capsule and 0.7 for injectables

Accordingly, the committee recommended as below by applying the Pronab Sen formula to Zinc Sulphate Dispersible Tablet 20 mg:

 $= 3.49[1+0.8{(11-20)/20}] = Rs. 2.23$ (excluding GST)

5. Agenda No. 5 - Retail price fixation under Para 5 of DPCO, 2013 - Each dose of 0.5ml containing Diphtheria Toxoid ≥ 30IU, Tetanus Toxoid ≥ 60IU,Inactiveated w-B.pertussis ≥4 IU Purified capsular polysaccharide of Haemophilus influenzae type beonjugated to 18-33 µg of Tetanus Toxoid (carrier protein) 10 µg, Inactivated Salk Poliovirus Type1* 40 DU**,Inactivated salk Poliovirus Type2*8 DU**, Inactivated Salk Poliovirus Type 3*32 DU**,Alumininium content(AI+++) (As Aluminium Phosphate gel NMT 1.25mg, 2-Phenoxyethanol 3.3mg and Physiological saline q.s. for M/s Panacea BiotecLtd. (Manufacturer and marketer).

5.1The matter relates to retail price fixation of Vaccine for M/s Panacea Biotec Limited. The matter was deliberated in the 48th meeting of the MDC held on 20.01.2023, wherein the committee noted that other similar vaccines (Easy Four TT, Easy FIVE TT, Easy Six) of the applicant company (M/s Panacea Biotec Ltd.) are available at much lower prices. After deliberating the matter, the committee had directed as follows:

- a. To check whether the applicant company has applied for retail price fixation of their other vaccines i.e. Easy Four TT, Easy FIVE TT and Easy Six? If yes, retail prices calculated; if not necessary action may be taken.
- b. The applicant company may be asked to present their case in next MDC

5.2 The committee noted the reply of the company dated 10.02.2023 wherein the company had stated that it had inadvertently submitted form I for price approval to NPPA and that the applied vaccine (Easy fourPol) is covered under Patent bearing No. 272351 dated 30.03.2016. Hence, it requested to ignore Form I application and consider the same under the exemption of pre approval of price as per Para 32 of DPCO 2013.

- 5.3 With respect to Easy Four TT, the company replied that it had obtained the price approval from NPPA and the price was notified by NPPA vide SO No. 6253 dated 21.12.2018.
- 5.4 With respect to Easy Five, it was informed by the company that this vaccine was non scheduled at the time of its launch and later when the ceiling price of the same was notified by NPPA in 2017, the same was implemented by the company
- 5.5 With respect to Easy Six, the company mentioned that it had filed an intimation regarding grant of patent no. 272351 corresponding to this product.
- 5.6 The committee deliberated upon the explanation of the company in detail and directed that:
 - M/s Panacea Biotec Limited may apply a fresh under Para 32 if the exemption is to be sought in respect of the applied new drug. The exemption under para 32 is not self-invocable. After receiving the application for exemption under Para 32, NPPA shall examine the same for further deliberations by MDC.
 - ii. Necessary action may be taken for the vaccine Easy Six in respect of which no exemption was sought by the company under para 32 from NPPA and the same was launched without price approval of NPPA.
- 6. Agenda No. 6-Retail Price fixation of formulation "Formoterol Fumarate Dihydrate 6mcg + Beclomethasone Dipropionate IP 100 mcg Inhaler (MDI) for M/s. Cipla Limited in view of DoP's Review Order dated 03.10.2022 reg.
- 6.1 The matter relates to the review order passed by DoP on 03.10.2022 w.r.t. review application dated 24.01.2020 against National Pharmaceutical Pricing Authority's ("NPPA" herein) notification SO. No. 2944(E) dated 14.08.2019 filed by M/s. Cipla Limited under para 31 of the Drugs (Prices Control) Order, 2013 in the matter of Retail Price fixation of formulation "Formoterol Fumarate Dihydrate 6mcg + Beclomethasone Dipropionate IP 100 mcg Inhaler (MDI).
- 6.2 The matter was deliberated in the 47th meeting of MDC held on 02.12.2022, wherein company representatives were also present. After detailed deliberations, the committee recommended that special pricing on account of improved formulations as claimed by M/s Cipla Limited may be considered for further examination, if the company submits published literature demonstrating the improved efficacy of its product and obtain the manufacturing permission/license from the licensing authorities along with the product label claim.
- 6.3The committee noted that a letter was sent to M/s Cipla Limited on 27.12.2022 requesting to submit the inputs by 10.01.2023. M/s Cipla Limited vide letter dated 09.01.2023 requested to allow one month time to submit their response. The committee was appraised that even as on date of meeting (23.02.2023), the requisite details have not been received.
- 6.4 The committee deliberated on the matter and directed that a reminder may be issued to M/s Cipla Limited giving one week time to submit the requisite detailsand if the same are not received within the due time, the matter shall be treated as closed.

- 7. Agenda No. 7-Retail price fixation under DPCO, 2013- Each ml contains Ibuprofen IP 100mg for M/s Akums Drugs & Pharmaceuticals (manufacturer) and M/s Cipla Ltd. (marketer) (F.No. 3099)
- 7.1. The matter relates to the retail price fixation of Each ml contains Ibuprofen IP 100mg for M/s Akums Drugs & Pharmaceuticals (manufacturer) and M/s Cipla Ltd. (marketer). The matter was deliberated in the 48th meeting of MDC held on 20.01.2023, wherein committee recommended retail price of Rs. 5.05 per ml calculated taking the ceiling price of Diclofenac Injection 25 mg/mlas base as against the claim price of Rs.26.78 per ml (excluding taxes) by the company.
- 7.2 The committee noted that M/s Cipla Limited had filed representation dated 07.02.2023stating that the drug with same dosage & strength is imported and sold by another company at prices almost double (i. e Rs. 74.375 per ML. Applicant has also stated that there are no other manufacturers of the said formulation and notifying retail price suggested by MDC will lead to discouragement of launches of innovative drugs in India. Therefore, applicant had requested to fix retail price in line with the market available formulation or as claimed by the company.
- 7.3 The committee deliberated on the matter and directed to collect the data from companies (suggested by M/s Cipla Limited and also identified from Websources) and Hospitals/Institutions in this respect and then resubmit the matter to MDC.

The meeting ended with a vote of thanks to all.

(RashmiTahiliani)
Jt. Director (Pricing)

Copy to:

All members of the Committee.

from firm coated tablet containing Dapaglifinzin Propanediol Monohydrate eq. to Dapagl flozin 10mg

Number of Companies consisting of Market Share of 1% & Above	14
Sum of N.AT value considered for price calculation (it. takhs)	38,870.13
Sum of PTR per unit considered for price calculation	206.47
Number of Packs considered	16
Average PTR	12,90
Add: 16% Retailer Margin	2.06
Retail Price (without local taxes)	14.96
% Reduction with compared to Highest Price	68.51%

Minimum Price (Rs.)	7.74
Maximum Price (Rs.)	40.96
Average of all considered (Rs.)	12.90
Retail Price (Rs.)	14.96

								4,46,92,95,067	1009	6		M3	
S.No.	पार कित्रम Pack Description	BRAND	कंपनी Company	Streugth	Pack Size	Unit	PTR	MAT(Rs.)	SKU wise MAT %	Brandwi se MAT (ignorin g O% MAT)	Qualify (Y/N) Y=Yes N=No	Price per unit (Rs.)	Price per unit (Rs.) Considered
3.1	4 DAPA 10 MG TABLET 10	4 DArA	4 CARE LIFESCIENCE PVT LYD	10 MG	10	TABLET	85.00	774860	0.02%	0.02%	N	8.50	
	6 DAPA VI 10 MG TABLET 10	4 DAPA M	4 CARE LIFESCIENCE PVT LTD	10 MG	10	TABLET	100.00	4300	0.00%	0.00%	N	10.00	4.7
3	BIOXIGA 10 MG TABLET 10	BIOXIGA	BIOS LAB PVT.LTD	10 MG	10	TABLET	102.85	698143	0.02%	0.02%	N	10.29	
4.	DAGLIPACK TO MIG TARLET 10	DAGLIPACK	KOYE PHARMACE UTICALS PVT, LTD.	10 MG	10	TABLET	99.29	5053067	0.11%	0.11%	N	9.93	
	DARO 16 MG 1 ABLET 15	DAJIO	MICRO LABS LTD	10 MG	15	TABLET	126.43	41671202	0.93%	0.93%	N	8,43	
6	DAMITA 10 MG TABLET 10	DAMITA	MACLEODS PHARMACEUTICALS PVT.LTD	10 MG	2.0	TABLET	206.43	96998896	2.17%	2.17%	Y	10.64	10.64
7 -	DAPA GOLD 10 MG TABLET 15	DAPA GOLD	IHBC LIFESCIENCES PVT LTD	10 MG	15	TABLET	150.00	15213495	0.34%	0.34%	N	10.00	
0	DAPAGEST 10 MG TABLET 10	DAPABEST	PANACEA BIOTEC LTD	10 MG	10	TABLET	100.00	12009600	0.27%	0.27%	N	10.00	
9 -	DAPABLE IC MG TABLET IC	DAPABICE	CORONA	10 MG	10	TABLET	117.07	106559125	2.38%	2.38%	Y	11.71	11.71
	DAPABLIS 10 MIG TABLET 10	DAPABLIS	MED MANOR ORGANICS PVT LTD.	10 MG	10	TABLET	82.14	459820	0.01%	0.01%	N	8.21	
11	DAPACARU 10 MG TABLET 10	DAPACARE	OCTALIFE PHARMACEUTICALS PVT.LTD	10 MG	10	TABLET	78.57	472441	0.01%	0.01%	N	7.86	
-	DAPACONIC 10 MG TABLET 15	DAPACONIC	LA RENON	10 MG	15	TABLET	181.07	3112774	0.07%	0.07%	N	12.07	
-	DAPACOTE 10 MG TABLET 10	DAPACOSE	JB CHEMICALS	10 MG	10	TABLET	94.25	36552896	0.82%	0.82%	N	9.43	
-	DAPACE 10 MG TABLET 10	DAPADEL	CADELL HEALTH CARE PVT.LTD	10 MG	10	TABLET	92.14	4137752	0.09%	0.09%	N	9.21	
-	DAPALASE 10 MG TABLET 10	DAPAEASE	JUBILAN' GENERICS LIMITED	10 MG	10	TABLET	103.57	1263968	0.03%	0.03%	N	10.36	
16	IDAPAFOR 10 MG TABLET 10	DAPAFOR	ZUVENTUS HEALTHCARE LTD	10 MG	10	TABLET	75.00	23400	0.00%	0.00%	N	7.50	
110		DAPAGAIN	SYSTOPIC LABORATORILS LTD-N:EM	10 MG	15	TABLET	63.22	14273749	0.32%	0.32%	N	4.21	
10	DAPAGAN 10 MG TABLET 15	DAPAGLYN	ZYDUS CADILA ZHL	10 MG	15	TABLET	200.36	264281592	5.91%	5.91%	Y	13.36	13.36
	THE REAL PROPERTY AND ADDRESS OF THE PARTY O	DAPAGREAT	SINSAN PHARMACEUTICALS	10 MG	15	TABLET	142.14	4690620	0.10%	0.10%	N	9.48	
19	DAT ACIN: AT 10 MG TABLET 15	DAPAGZA	EMCURE PHARMACEUTICALS LTD	10 MG	15	TABLET	159.64	925273	0.02%	0.02%	N	10.64	THE PARTY NAMED IN
50	DAPAGZA 10 MG TABLET 15	DAPAHENZ	LA RENON	10 MG	15	TABLET	181.07	9395541	0.21%	0.21%	N	12.07	
21	DAPAHENZ 10 MG TABLET 15	DAPAKEY	PRECIA PHARMA	10 MG	10	TABLET	103.57	7689762	0.17%	0.17%	N	10.36	
44	DAPAKEY 10 MG TABLET 10	DAPALEX	AJANTA PHARMA LTD	10 MG	10	TABLET	110.71	38055596	0.85%	0.85%	N	11.07	
23	DAPALEX 10 MU TABLET 10	DAPAMAC	MACLEODS FHARMACEUTICALS PVT.LTD	10 MG	10	TABL!	106.43	156124378	3.49%	3.49%	Y	10.64	10.64
	DAPAMAC 10 MG TAPLET 13	DAPANORM	ALKEM LABORATORIES LTD.	10 MG	10	TABLET	125.00	218550500	4.89%	4.89%	Y	12.50	12.50
2F	DAPANCRIA 10 MY TABLLE 10	DAPANOVA	MEDLEY PHARMACEUTICALS	10 MG	15	TABLET	140.71	44151339	0.99%	0.99%	N	9.38	
	DAFANOVA 10 MC TABLET 15		MISN LABORATORIES LTD	10 MG	10	TABLET	107.14	30543578	0.68%	0.68%	N	10.71	
	DAF 40NF 10 MG TABLET 10	DAPAONE	ICON LIFESCIENCES	110 MG	10	TABLET	69.64	1092721	0.02%	0.02%	N	6.96	
	DAPARAY 10 MG TABLET 10	DAFARAY		10 MG	10	TABLE?	92.86	209664637	4.69%	4.69%	Y	9.29	9.29
29	DAPASYL 10 MG TABLET 10	DAPARYL	INTAS PHARMACEUTICALS LTD	10 MG	10	TABLET	99,29	8350885	0.19%	0.19%	N	9.93	7.11.7
- 30	DAPASIS 10 MG TABLE* 10	DAPASIS	AKESISS PHARMA (P) ITO		10	TABLE	96.43	1868421	0.04%	0.04%	N	9.64	
-	DAPASPI C 10 NIG TABLET 10	DAPASPEC	SPECTRA THERAPEUT CS PVT. LTD.	120 MG	15	TABLE	117.54	327937	0.01%	0.01%	N	7.84	
-	DA' ATEN AO MY TABLET 15	DAPATEN	BALPHARVA	10 MG	14	TABLIT	117.86	6208185	0.14%	0.14%	N	8.42	
	CAPATREND 10 MG TABLET 14	DAPATREND		10 MG		IABLIT	103.57	33750874	0.76%	0.76%	N	10.36	
	DAPATERN LU MUTABLET 10	DAPATURA		10 MG	10	TABLET	92.86	259692316	5.81%	5.81%	Y	9.29	9.29
15	DAPAYEL 10 MG TABLE LC	DAPAVEL	UN AS PHARM ACHITICALS L.U	10 MG	10	1142721	760	237072310	3.0170	3.0170	1	1 160	3.43



36	DAPAYES 10 MG TABLET 10	DAPAYES	ANAX LIFE SCIENCES PVT.LTD	10 MG	10	TABLET	103.57	107402	0.00%	0.00%	N	10.36	
7	DAPAZOL 10 MG TABLET 10	DAPAZOL	ALTEUS BIOGENICS PVT.LTD.	10 MG	10	TABLET	106.07	613976	0.01%	0.01%	N	10.61	
8	DAPEFY 10 MG TABLET 14	DAPEFY	SUN PHARMA LABORATORIES LTD.	10 MG	14	TABLET	129.00	13696722	0.31%	0.31%	N	9.21	
9	DAPGLIN 10 MG TABLET 10	DAPGLIN	VASU ORGANICS PVT.LTD	10 MG	10	TABLET	83.57	10363	0.00%	0.00%	N	8.36	
0	DAPIXA 10 MG TABLET 10	DAPIXA	TAS MED (INDIA) PRIVATE LTD.	10 MG	10	TABLET	100.00	820100	0.02%	0.02%	N	10.00	
1	DAPLO 10 MG TABLET 10	DAPLO	DR. REDDYS LABORATORIES LTD	10 MG	10	TABLET	117.86	83513921	1.87%	1.87%	Y	11.79	11.79
2	DAPNAT 10 MG TABLET 30	DAPNAT	NATCO PHARMA LTD	10 MG	30	TABLET	417.86	20465947	0.46%	0.46%	N	13.93	
3	DAPRICA 10 MG TABLET 10	DAPRICA	APRICA HEALTHCARE PVT LTD	10 MG	10	TABLET	103.57	12433268	0.28%	0.28%	N	10.36	
14	DAXIGA 10 MG TABLET 10	DAXIGA	ACMEDIX PHARMA LLP	10 MG	10	TABLET	49.29	5898189	0.13%	0.13%	N	4.93	A
15	DEPAJA 10 MG TABLET 10	DEPAIA	INDOCO REMEDIES LTD	10 MG	10	TABLET	82.14	5213590	0.12%	0.12%	N	8.21	
6	DEXIGLU 10 MG TABLET 10	DEXIGLU	FUSION HEALTHCARE PVT LTD	10 MG	10	TABLET	103.57	13208075	0.30%	0.30%	N	10.36	
17	DGSON 10 MG TABLET 10	DGSON	UNISON PHARMACEUTICALS	10 MG	10	TABLET	32.14	3618000	0.08%	0.08%	N	3.21	
8	DIABFLOZ 10 MG TABLET 10	DIABFLOZ	FINECURE PHARMACEUTICALS	10 MG	10	TABLET	82.14	4035374	0.09%	0.09%	N	8.21	
19	DIABIZ (BLUE) 10 MG TABLET 15	DIABIZ (BLUE)	BLUE CROSS LABORATORIES LTD	10 MG	15	TABLET	75.00	4270125	0.10%	0.10%	N	5.00	
0	DIFLUP 10 MG TABLET 10	DIFLUP	EXELTIS	10 MG	10	TABLET	110.71	281757	0.01%	0.01%	N	11.07	
1	DIFOZIN 10 MG TABLET 14	DIFOZIN	LINCOLN PHARMACEUTICALS LTD	10 MG	14	TABLET	149.29	133615	0.00%	0.00%	N	10.66	
2	DIMPRIDE 10 MG TABLET 10	DIMPRIDE	INDCHEMIE HEALTH SPECIALITIES PVT. LTD.	10 MG	10	TABLET	125.00	128000	0.00%	0.00%	N	12.50	
3	DINECA 10 MG TABLET 14	DINECA	APOSTLE REMEDIES	10 MG	14	TABLET	100.00	163900	0.00%	0.00%	N	7.14	
4	DIOSGLT 10 MG TABLET 15	DIOSGLT	DIOS LIFESCIENCES PRIVATE LIMITED	10 MG	15	TABLET	133.93	499425	0.01%	0.01%	N	8.93	*** * *
5	DIUTEN 10 MG TABLET 10	DIUTEN	WOCKHARDT LTD	10 MG	10	TABLET	103.58	29518	0.00%	0.00%	N	10.36	The state of the s
6	DMBEST 10 MG TABLET 10	DMBEST	KEPLER HEALTH CARE	10 MG	10	TABLET	92.86	29622	0.00%	0.00%	N	9.29	
	DPO 10 MG TABLET 10	DPO	RPG LIFE SCIENCES LTD.	10 MG	10	TABLET	85.71	380381	0.01%	0.01%	N	8.57	
17	ELDAPA 10 MG TABLET 10	ELDAPA	EL-DORADO BIO-TECH PVT LTD	10 MG	10	TABLET	71,43	78074	0.00%	0.00%	N	7.14	
	EMILDAP 10 MG TABLET 15	EMILDAP	EMCURE PHARMACEUTICALS LTD	10 MG	15	TABLET	159.64	4847149	0.11%	0.11%	N	10.64	
9		ESGEDAP		10 MG	14	TABLET	145.00	520695	0.01%	0.01%	N	10.36	
0	ESGEDAP 10 MG TABLET 14		EAST WEST PHARMA	10 MG	15	TABLET	139.29	2340629	0.05%	0.05%	N	9.29	
1	FLOZIMAX 10 MG TABLET 15	FLOZIMAX	ALNICHE LIFE SCIENCES PVT.LTD		10	TABLET	100.00	195400	0.00%	0.00%	N	10.00	
12	FLOZIPA 10 MG TABLET 10	FLOZIPA	WALLACE PHARMACEUTICALS LTD.	10 MG	14	TABLET	300.00	662391900	14.82%	14.82%	Y	21.43	21.43
53	FORXIGA 10 MG TABLET 14	FORXIGA	ASTRAZENECA PHARMA INDIA LTD	10 MG		TABLET	573.50	62988652	1.41%	1.41%	Y	40.96	40.96
54	GLEDEPA 10 MG TABLET 14	GLEDEPA	ABBOTT HEALTHCARE PVT. LTD	10 MG	14	TABLET	103.57	3536191	0.08%	0.08%	N	10.36	40.90
65	GLIFOPRIME 10 MG TABLET 10	GLIFOPRIME	PRIMUS REMEDIES PVT LTD	10 MG	10			144016069		3.22%	Y	8,93	8.93
66	GLUCRETA 10 MG TABLET 10	GLUCRETA	TORRENT PHARMACEUTICALS LTD.	10 MG	10	TABLET	89.25		3.22%			-	8.93
67	GLUFLOZIN 10 MG TABLET 15	GLUFLOZIN	ARISTO PHARMACEUTICALS PVT.LTD	10 MG	15	TABLET	107.14	. 26823999	0.60%	0.60%	N	7.14	
18	GLUJECT 10 MG TABLET 15	GLUJECT	ABBOTT HEALTHCARE PVT. LTD	10 MG	15	TABLET	160.71	3143166	0.07%	0.07%	N	10.71	10.20
59	GLUXIT 10 MG TABLET 10	GLUXIT	ERIS LIFESCIENCES LTD	10 MG	10	TABLET	103.57	291498490	6.52%	6.52%	Y	10.36	10.36
70	JODAPA 10 MG TABLET 15	JODAPA	JARUN PHARMACEUTICALS	10 MG	15	TABLET	107.14	1409320	0.03%	0.03%	N	7.14	
71	JUSTOZA 10 MG TABLET 10	JUSTOZA	MANKIND PHARMACEUTICALS LTD.	10 MG	10	TABLET	70.71	44021854	0.98%	0.98%	N N	7.07	•
72	LVEFFECT 10 MG TABLET 15	LVEFFECT	ABBOTT HEALTHCARE PVT. LTD	10 MG	15	TABLET	160.71	350669	0.01%	0.01%	N	10.71	
73	MDAPA 10 10 MG TABLET 10	MDAPA 10	SINSAN PHARMACEUTICALS	10 MG	10	TABLET	96.43	2815370	0.06%	0.07%	N	9.64	
74	MDAPA 10 10 MG TABLET 15	MDAPA 10	SINSAN PHARMACEUTICALS	10 MG	15	TABLET	96.43	249079	0.01%	0.07%	N	6.43	
75	MYODA 10 MG TABLET 10	MYODA	ERIS LIFESCIENCES LTD	10 MG	10	TABLET	103.57	9345018	0.21%	0.21%	N	10.36	
76	OPSICA 10 MG TABLET 15	OPSICA	OPSISCARE LIFESCIENCSE PVT LTD	10 MG	15	TABLET	150.00	1332150	0.03%	0.03%	N	10.00	100
77	OXRA 10 MG TABLET 14	OXRA	SUN PHARMA LABORATORIES LTD.	10 MG	14	TABLET	129.00	811750613	18.16%	18.16%	Y	9.21	9.21
78	SGLTD 10 MG TABLET 10	SGLTD	MANKIND PHARMACEUTICALS LTD.	10 MG	10	TABLET	70.71	4635606	0.10%	0.10%	N	7.07	
79	SINXIGA 10 10 MG TABLET 10	SINXIGA 10	SINSAN PHARMACEUTICALS	10 MG	10	TABLET	96.43	75119	0.00%	0.00%	N	9.64	
80	SUGAFLO 10 MG TABLET 15	SUGAFLO	LLOYD HEALTHCARE PVT.LTD	10 MG	15	TABLET	160.72	13258436	0.30%	0.30%	N	10.71	
81	SWITDAPA 10 MG TABLET 10	SWITDAPA	AKUMENTIS HEALTHCARE LTD	10 MG	10	TABLET	85.00	3315765	0.07%	0.07%	N	8.50	
82	T2C 10 MG TABLET 15	T2C	IPCA LABORATORIES PVT LTD.	10 MG	15	TABLET	182.14	20824066	0.47%	0.47%	N	12.14	
83	UDAPA 10 MG TABLET 10	UDAPA	USV PVT LTD	10 MG	10	TABLET	94.29	339639891	7.60%	7.60%	Y	9.43	9.43
34	VIVADAPA 10 MG TABLET 10	VIVADAPA	MITOCH PHARMA PVT LTD	10 MG	10	TABLET	100.00	.11705700	0.26%	0.26%	N	10.00	
85	VOAGE 10 MG TABLET 10	VOAGE	ALEMBIC LTD	10 MG	10	TABLET	77.43	87364082	1.95%	1.95%	Y	7.74	. 7.74
86	XGLET 10 MG TABLET 10	XGLET	ELINOR PHARMA	10 MG	10	TABLET	140.00	7840	0.00%	0.00%	N	14.00	
87	ZANELLA 10 MG TABLET 10	ZANELLA	CADOMED PHARMACEUTICALS INDIA PVT.LTD	10 MG	10	TABLET	79.07	1553093	0.03%	0.03%	N	7.91	Bearing EV
88	ZINODAP 10 MG TABLET 10	ZINODAP	WOCKHARDT LTD	10 MG	10	TABLET	103.57	17088429	0.38%	0.38%	N	10.36	100
89	ZUCAPRIDE 10 MG TABLET 15	ZUCAPRIDE	MICRO LABS LTD	10 MG	15	TABLET	137.86	91977644.62	2.06%	2.06%	Y	9.19	9.19
	The state of the s												
		Rs. Per Tablet											
	Market and the second second				A TOTAL OF								
_			96 Excluding GST								Harris Street		



Computation of Retail Price based on June, 2022 Data under Para S of DPCO, 2013		
	Number of Companies consisting of Market Share of 1% & Above	2
	Sum of MAT value considered for price calculation (in Lakhs)	17,801.66
bach från coated tablet containing Sitagliptin Phosphate Monohydrate eq. to Sitagliptin 100 mg	Sum of PTR per unit considered for price calculation	91.79
	Number of Packs considered	3
	Average PTR	30.60
	Add: 16% Retailer Margin	4.90
	Retail Price (without local taxes)	35.50
·	% Reduction with compared to Highest Price	4.79%

Minimum Price (Rs.)		27.55
Maximum Price (Rs.)		32.14
Average of all considered (Rs.)	-	30,60
Retail Price (Rs.)		35.5

								1,78,01,66,498	100%			М3	
S.No.	रेक क्षित्रच Pack Description	L	संबद्ध Company	Strength	Pack Size	Unit	PTR	` '	SKU wise MAT %	Brandwi se MAT (Ignorin g 0%	Y/N)		Price per unit (Rs.) Considered
1	ISTAVEL 100 MG TABLET 7	ISTAVEL	SUN PHARMA LABORATORIES LTD.	100 MG	7.	TABLET	225.00	435630150	24.47%	MAT) 24.47%	Y	32.14	32.14
2	JANUVIA 100 MG TABLET 15			100 MG		TABLET	481.57	126871543	7.13%	75.53%	Y	32.10	32.10
3	JANUVIA 100 MG TABLET 7		MSD PHARMACEUTICALS PRIVATE LTU.	100 MG		TABLET	192.86	1217664806	68.40%	75.53%	Y	27.55	27.55
		Rs. Per Tablet		_									
	Worked out Retail Price	35.50	Excluding GST	L		<u> </u>	<u> </u>				<u> </u>	<u> </u>	نـــــــــــــــــــــــــــــــــــــ

. .

Each, uncoated bijayered tablet contains: Vildagliptin 100 mg (as sustained release)

Number of Companies consisting of Market Share of 1% & Above	
	18
Sum of MAT value considered for price calculation (in Lakhs)	8.157.94
Sum of PTR per unit considered for price calculation	214.69
Number of Packs considered	22 •
Average PTR	9,76
Add: 16% Retailer Margin	1.56
Retail Price (without local taxes)	11.32
% Reduction with compared to Highest Price	G4.04%

Minimum Price (Rs.)	7.07
Maximum Price (Rs.)	27.14
Average of all considered (Rs.)	9.76
Retail Price (Rs.)	11,32

C 32.	A-c-							84,82,08,341				M3	
S.No.	र्के जिल्ला Pack Description	BRAND	ਸ਼ੇਖਰੀ Company	Strength	Pack Size	Unit	PTR	MAT(Rs.)	SKU wise MAT %		Qualify (Y/N) Y=Yes N=No	Price per unit (Rs.)	Price per unit (Rs.) Considered
-	ABVIDA 100 MG TABLET SR 15	ABVIDA	ALUCATION AND AND AND AND AND AND AND AND AND AN										
	BIOVILDA 100 MG TABLET SR 10	BIOVILDA	ABBOTT HEALTHCARE PVT. LTD	100 MG	15	TABLET SR	139.29	12960238	1.53%	1.53%	Y	11.29	9.29
	ENCELIN OD 100 MG TABLET 10	ENCELIN	- BIOS LAB PVT.LTD	100 MG	10	TABLET SR	90.00	439740	0.05%	0.05%	N	9,00	<u> </u>
	GALVUS OD 100 MG TABLET 1S	GALVUS	TORRENT PHARMACEUTICALS LTD.	100 MG	· 10	TABLET	78.57	39774884	4.69%	4.69%	Y	7.86	7.86
	GUPACURE OD 100 MG TABLET 15	GLIPACURE	NOVARTIS INDIA LTD	100 MG	15	TABLET	407.15	45654544	5.38%	5_38%	Y	27.14	27.14
	GUFTAGREAT OD 100 MG TABLET 10		HBC LIFESCIENCES PVT LTD	100 MG	15	TABLET	117.86	220045	0.03%	0.03%	N	7.86	
 	GLIPY OD 100 MG TABLET SR 15	GLIPTAGREAT	MANKIND PHARMACEUTICALS LTD.	100 MG	10	TABLET	70.71	36313545	4.28%	4.28%	Y	7.07	7.07
	GLIVILDA OD 100 MG TABLET 15	GUPY	ALEMBIC LTD	100 MG	15	TABLET SR	128.57	11088905	1.31%	1.31%	Y	8.57	B.57
9		GLUVILDA	ALKEM LABORATORIES LTD.	100 MG	15	TABLET	117.86	46010997	5.42%	5.42%,	<u> Y</u>	7.86	7.86
10	(BVILDA OT) 100 MG TABLET SR 10	IBAITUV	INDIAGULLS PHARMACEUTICALS LTD	100 MG		TABLET SR	N 89.29	522257	0.06%	0.06%	N	8.93	
11		INTAGLIP	INTAS PHARMACEUTICALS LTD	100 MG		TAULIT	107.07	28280827	3.33%	3.33%	Y	10.71	10.71
12	JALRA OD 100 MG TABLET 10	JALRA	USV PVT LTD	100 MG		TABLET	128.57	186252545	21.96%	21.96%	Y	12.86	12.86
	ILIIVILDA 100 MG TABLET 15	JUBIVILDA	INBILANT GENERICS LIMITED	100 MG		TABLET	107.14	2361044	0.28%	0.28%	N	7.14	
	C VILDALOG 100 MG TABLET 10	O VILDALOG	WOCKHARDT LTD	100 MG	10	TABLET	142.86	7152286	0.84%	0.84%	N I	14.29	
	TORGUP OD 100 MG TABLET 10	TORGLIP	TORRENT PHARMACEUTICALS LTD	100 MG		TAULET	78.57	23659391	2.79%	2.79%	ΥΥ	7.96	7.86
	VERIFICA 100 MG TABLET SR 10	VERIFICA	LUPIN LTD	100 MG		TABLET SR	114.29	24800587	2.92%	2.92%	Y	11.43	11.43
	PISTI. 200 BIG TABLET SR 15	VIBITE	CORONA	100 MG	15	TABLET SR	116.68	8617292	1.02%	1.02%	Y	7,78	7.78
	VIDAGLO OD 100 MG TABLET 10	VIDAGLO	MEDLEY PHARMACEUTICALS	100 MG		TABLET	92.86	2619488	0.31%	0.31%	N	9.29	
	VILACT 100 MG TABLET XR 10	VILACT	MANKIND PHARMACEUTICALS LTD.	100 MG	10	TABLET XR	107.14	1302072	0.15%	0.15%	N	10.71	
	V-LAPIL SR 100 MG TABLET 10	VILAPIL SR	CADELL HEALTH CARE PVT.LTD	100 MG	10	TABLET	67.86	111019	0.01%	0.01%	N	6.79	·
	VILASON CO 100 MG TABLET 10	VILASON	UNISON PHARMACEUTICALS	100 MG	10	TAULT	42.86	794153	0.09%	0.09%	N	4.29	
	VILATIN 100 MG TABLE! SR 15	VILATIN	AJANTA PIKARMA LTD	100 MG	15	TABLET SR	128.93	15584350	1.84%	1.84%	Y	8.60	8.60
	VILDADLIS 100 MG TABLET SR 10	VILDABLIS	MED MANOR ORGANICS PVT LTD.	100 MG	10	TABLET SR	85.71	12321	0.00%	0.00%	N	8.57	
	VILDAMAC OD 100 MG TABLET 15	VILUAMAC	MACLEODS PHARMACE UTICALS PVT.LTD	100 MG	15	CABLET.	128.57	24494771	2.89%	2.89%	Y	8.57	8.57
	VILDAMHIC OD 100 MG TABLET 10	VILDAMBIC	ALEMBIC LTD	100 MG	10	TABLLT	70.71	648764	0.08%	0.08%	N	7.07	
	VILDANA 100 MG TABLET SR 10	VILDANA	AKESISE PHARMA (P) LTD	100 MG	10	TAULET SR	85.00	5428100	0.64%	0.64%	N	8.50	
	VII DANI X 5R 100 MG TABLET 10	VILDANEX SR	LLOYD HEALTHCARE PVT.LTD	100 MG	10	TABLET	78.58	4949754	0.58%	0.58%	N	7.86	
27	VILDAPRIDE OD 100 MG TABLET 10	VILDAPRIDE	MICRO LABS LTD	100 MG	10	TAULET	85.71	23647646	2.79%	2.79%	<u>?</u>	8.57	8.57
28	VILDAPRIME 100 MG TABLET SR 15	VILDAPRIME	PRIMUS REMEDIES PVT LTD	100 MG	15	TABLET SR	117.86	1393695	0.16%	0.16%	N	7.86	- 0.57
29	VILIDARAY SR 100 MG TABLET 10	VILDARAY SR	LLOYD HEALTHCARE PVT.LTD	100 MG	10	TABLE?	78.58	13051431	1.54%	1.54%	Ÿ	7.86	7.86
30	VILDASII C 100 MG TABLET SR 10	VILDASPEC	SPECTRA THERAPEUTICS PVT. LTD.	100 MG	10	TABLET SR	67.96	643041	0.08%	0.08%	N	6,79	7.00
31	VILMUR OD 100 MG TABLET 15	VILMUR	OPSISCARE LIFESCIENCSE PVT LTD	100 MG		TABLET	106.07	199199	0.02%	0.02%	N	7.07	
.32	VILPOWER OD 100 MG TABLET 15	VILPOWER	MICRO LAUS LTD	100 MG		TABLET	128.57	11333703	1.34%	1.34%	'' Y	8.77	8.57
33	VILSURE 100 MG TABLET SR 15	VILSURE:	SINSAN PHARMACEUTICALS	100 MG		TABLET SR	160,71	622751	0.07%	0.07%	N	10.71	6.57
34	VI TAB 100 MG TABLET SR 15	VILTAB	ALTEUS BIOGENICS PVT.LTU.	100 MG		TABLET SR	96.43	74059	0.01%	0.01%	- N	6.43	
.15	VINGLYN 100 MG TABLIT SR 10	VINGLYN	ZYDUS CADILA - ZHL	100 MG		TABLET SR	86.04	17002984	2.00%	2.00%	- N	6.43 6.60	200
	VSM ALL OD 100 MG TABLET 10	VSMALL.	DR. REDDYS LABORATORIES LTD	100 MG		TABLET	71.43	2920558	0.34%	0.34%	- 1 -	7.14	B.60
37	WLDA OD 100 MG TABLET 15	VYLDA	EMCURE PHARMACEUTICALS LTD	100 MG		TABLET	159.64	8524536S	10.05%	10.05%	- <u>N</u>		10.01
	VYSOV 100 MG TABLET XR 15	vysov	CPLA LTD.	100 MG		TABLET XR	138.21	45645511	5.38%	5.38%	- <u>Y</u>	10.64	10.64
	ZAVA OD 100 MG TABLET 10	ZAVA	INTAS PHARMACI UTICALS LTD	100 MG	 	TABLET	107.07	56779649	6.69%	6.69%	Y	9.21	9.21
	COMPLES LOD MED TABLET SR 10	ZOMELIS	FRIS LIFESCIENCES LTD	100 MG	-	TABLET SR	78.57	41845910.58	4.93%	4.93%	- Y	10.71 7.86	10.71 7.86

41 ZUKANORM 100 MG TABULT SR 10	ZUKANORM	MANKIND PHARMACEUTICALS LTD.	100 MG	10	TABLET SK	70.71	17748917.1	2.09%	2.09%	Y	7.07	7.07
	Rs. Per Tablet			ļ <u> </u>								
Worked out Retail Price	1:	.32 Excluding GST		<u> </u>	1			<u> </u>				<u> </u>

Computation of Retail Price based on July, 2022 Data under Para 5 of DPCO, 2013		
	Number of Companies consisting of Market Share of 1% & Above	18
	Sum of MAT value considered for price calculation (in Lakhs)	8.805.80
Eath uncoated bilavered tablet contains Vildayliptin 100 my (2s sustained release)	Sum of PTR per unit considered for price calculation	217.45
•	Number of Packs considered	22
	Average PTR	9,88
	Add: 16% Retuiler Margin	1.58
	Retail Price (without local taxes)	11.46
	% Reduction with compared to Highest Price	63.60%

Minimum Price (Rs.)	7,07
Maximum Price (Rs.)	27.14
Average of all considered (Rs.)	9.88
Retail Price (Rs.)	11.46

S.No.	पैक निवाण		-1	- r				91,60,17,884	100%			M3	
3.NU.	Pack Description	BRAND	कंपरी Company	Strength	Pack Size	Unit	PTR	MAT(Rs.)	SKU wise MAT %	se MAT	Y/N)	Price per unit (Rs.)	Price per unit (Rs.) Considered
	***								1	,			
— <u>:</u> —	ABVIDA 100 MG TABLET SR 15	ABVIDA	ABBOTT HEALTHCARE PVT. LTD	100 MG	15	TABLET SR	139.29	14950414	1.63%	1.63%	Y	9.29	9.29
	FIOVEDA 100 MG TABLET SR 10	BIOVILDA	BIOS LAB PVT.LTD	100 MG	10	TABLET SR	90.00	455040	0.05%	0.05%	N	9.00	
	ENCEUN OD 100 MG TABLET 10	ENCELIN	TORRENT PHARMACEUTICALS LTD.	100 MG	10	TABLET	78.57	41801361	4.56%	4.5693	Υ	7.86	7.86
. 5	GALVUS OD 100 MG TABLET 15	GALVUS	NOVARTIS INDIA LTD	100 MG	15	TABLET	407.15	51393730	5.61%	5.61%	Y	27.14	27.14
	GLIPACURE OD 100 MG TABLET 15	GLIPACURE:	RBC LIFESCIENCES PVT LTD	100 MG	15	TABLET	117,86	272139	0.03%	0.03%	N	7.86	· -
- " -	CLIPTAGREAT OD 100 MG TABLET 10 GLIPY OD 100 MG TABLET SR 15	CLIPTAGREAT	MANKIND PHARMACE UTICALS LTD.	100 MG	10	TABLET	70.71	40022567	4.37%	4.37%	Y	7.07	7.07
-		GLIPY	ALEMBIC LTD	100 MG	15	TABLET SR	120.57	13885431	1.52%	1.52%	Y	8.57	8.57
9	GLUVILDA OD 100 MG TABLET 15	GLUVILDA	ALKEM LABURATORIES LTD.	100 MG	15	TARLET	117.86	48593451	5.30%	5.30%	Υ	7.86	7.86
10	IBVILDA OD 100 MG TABLET SR 10	IBVILDA	INDIABULLS PHARMACEUTICALS LTD	100 MG		TABLET SR .	89.29	578063	0.06%)	0.06%	N_	8.93	
11	INTAGLIP OD 100 MG TABLET 10	INTAGLIP	INTAS PHARMACEUTICALS LTD	100 MG	10	TABLET	107.07	29689119	3.24%	3.24%	Y	10.71	10.71
$-\frac{11}{12}$	JALKA OD 100 MG TABLET 10	IALRA	USV PVT LTD	100 MG	10	TABLET	128.57	198951147	21.72%	21.72%	Y	12.86	12.86
- <u>14</u> -	JUBIVILDA 100 MG TABLET 15	TUBIVILDA	JUBILANT GENERICS LIMITED	100 MG	15	TABLLT	107.14	2681500	0.29%	0.29%	N	7.14	
	O VILDALOG 100 MG TABLET 10	O VILDALOG	WOCKHARDT LTD	100 MG	10	TABLET	142.86	6549702	0.72%	0.72%	N	14.29	
14_	TORGUP OD 100 MG TABLET 10	TORGLIP	TORRENT PHARMACEUTICALS LTD.	100 MG	10	TABLET	70.57	25488029	2.78%,	2.78%	Y	7.86	. 7.86
.15	VERIFICA 100 MG TABLET SR 10	VERIFICA	LUPIN LTD	100 MG	10	TABLET SR	114.29	26813920	2.93%	2.93%	Y	11.43	11.43
	VIBITE 100 MG TABLET SR 15	VIBITE	CORONA	IOU MG	15	TABLET SR	116.68	9642863	1.05%	1.05%	_ Υ	7.78	. 7.78
17	VIDAGLO OD 100 MG TABLET 10	VIDAGLO	MEDLEY PHARMACEUTICALS	100 MG	10	TABLÉT	92.86	3250286	0.35%	0.35%	N	9.29	
18	VILACT 100 MG TABLET XR 10	VILACT	MANKIND PHARMACEUTICALS LTD.	100 MG	10	TABLET XR	107.14	1404177	0.15%	0.15%	N	10.71	
	VILAPIL SR 100 MG TABLET 10	VILAPIL SR	CADELL HEALTH CARE PVT.LTD	100 MG	10	TABLET	67.86	192180	0.02%	0.02%	N	6.79	
	VILASON OD 100 MG TABLET 10	VILASON	UNISON PHARMACEUTICALS	100 MG	10	TABLET	42.86	1008282	0.11%	0.11%	_ N	4.29	
21	VILATIN 100 MG TABLET SR 15	VILATIN :	AJANTA PHARMA LTD	100 MG	15	TABLET SR	128.93	15933383	1.74%	1.74%	Y	8.60	8.60
22	VILINABLIS 100 MG TABLET SR 10	VILDABLIS	MED MANOR ORGANICS PVT LTD.	100 MG	10	TABLET SE	85.71	15235	0.00%	0.00%	N	8,57	
23	VILINAMAC OD 100 MG TABLET 15	VILDAMAC	MACLEODS PHARMACEUTICALS PVT,LTD	100 MG	15	TABLET	128,57	27104999	2.96%	2.96%	Y	8.57	8.57
24	VILDAMBIC OD 100 MG TABLET 10	VILDAMBIC	ALEMBIC LTD	100 MG	10	TABLIT	70.71	846116	0.09%	0.09%	N	7.07	
25	VILDANA 100 MG TABLET SR 10	VILDANA	AKESISS PHARMA (P) LTD	100 MG		TABLET SR	85.00	5820800	0.64%	0.64%	N	8.50	
26	VILDANEX SR 100 MG TABLET 10	VILDANEX SR	LLOYD HEALTHCARE PVT.LTD	100 MG	10	TABLET	78.58	5381001	0.59%	0.59%	N	7.86	
27	VILDAPRIDE OD 100 MG TABLET 10	VILDAPRIDE	MICRO LABS LTD	100 MG	10	TABLIT	85.71	25029977	2.734)	2.73%	Y	8.57	8.57
28	VILDAPRIME 100 MG TABLET SR 15	VILDAPRIME	PRIMUS REMEDIES PVT LTD	100 MG	15	TABLET SR	117.86	1741028	0.19%	0.19%	N	7.86	
29	VILDARAY SR 100 MG TABLET 10	VILDARAY SR	LLOYD REALTHCARE PVT.LTD	100 MG	10	TABLL T	78.58	14385012	1.57%	1.57%	Y	7.86	7.86
	VILDASPIC 100 MG TABLET SR 10	VILDASPEC	SPECTRA THERAPEUTICS PVT. LTD.	100 MG	10	TABLET SR	74.65	694667	0.08%	0.08%	N	7,47	
31	VILMUR OD 100 MG TABLET 15	VILMUIL	OPSISCARE LIFE SCIENCISE PVT LTD	188 MG.	15	TABLET	106.07	284480	0.03%	0.03%	N	7.07	
	VILPOWER OD 100 MG TABLET 15	VILPOWER	MICRO LABS LTO	100 MG	15	TABLIT	128.57	12343749	1.35%	1,35%	Ÿ	8.57	8.57
	VILSURI 100 MG TABLET SR 15	VILSURE	SINSAN PHARMACEUTICALS	100 MG	15	TABLET SR	160.71	582092	0.06%	0.06%	N	10.71	
	VILTAB 100 MG TABLET SR 15	VILTAB	ALTEUS BIOGENICS PVT.LTD.	100 MG	15	TABLET SR	96.43	88523	0.01%	0.01%	N	6.43	
	VINGLYN 100 MG TABLET SR 10	VINGLYN	ZYDUS CADILA - ZHL	Ital MG	10	TABLET SR	86,04	18207301	1.99%	1.99%	Y	B.60	8.60
36	VINSURIN OD 200 MG TABLET 10	VINSORIN	FUSION HEALTHCARE PVT LTD	100 MG	10	TABLET	89.29	254387	0.03%	0.03%	Ň	8.93	5,00
	VSMALL OD 100 MG TABLET 10	VSMALL	DR. REDDYS LABORATORIES LTD	100 MG	10	TABLET	71.43	3338567	0.36%	0.36%	N	7.14	
	WYLDA OD 100 MG FABLET 15	VYLDA	EMCURE PHARMACEUTICALS LTD	100 MG	15	TABLEY	175.43	91545883	9,99%	9.49%	Y	11.70	11.70
	VYSOV 100 MG TABLET XR 15	vysov	CIPLA LTD.	100 MG	15	TABLET XR	138.21	50346586	5.50%	5.50%	Y	9.21	9.21
40	ZAVA OD 100 MG TABLET 10	ZAVA	INTAS PHARMACEUTICALS LTD	100 MG	10	TABLET	117.14	60560882	6.61%	6.61%	Ÿ	11.71	11.71

41 ZOMELIS 100 MG TABLET SR 10	ZOMELIS	ERIS LIFESCIENCES LTD	ICO MG	10	TAULET SR	8S.64	444244440	4.05"1	1000			
42 ZUKANURM 100 MG TABLET SR 10		MANKIND PHARMACEUTICALS LTD.	100 MG	10	TABLET SR	70.71	44424414,18 19465402,35	4.85% 2.13%	4.85%	- Y	8,56	8.56
					INGLET BY	70.71	17403402313	2.1.570	_2.13%	<u> </u>	7.07	7.07
	Rs. Per Tablet				-							
III 1 I I I I I I I I I I I I I I I I I							· · · · · ·				 	
Worked out Retail Price	11.46	Excluding GST						-	_		 	

ξ